Advaxis pharma partners with Merck& Co. for a clinical trial collaboration agreement.
Advaxis is developing and hoping to commercialize cancer immunotherapies based on a propriety platform that uses engineered Listeria monocytogenes to redirect the immune system to kill caner.
The planned Phase I/II clinical trial will evaluate the safety and efficacy of Advaxis’ ADXS-PSA as a standalone treatment and also in combination with Merck’s pembrolizumab, an injectable monoclonal antibody, in patients with previously treated metastatic prostate cancer.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Agreements with Merck & Co. 2009-2014
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity